RxDoctor Payments DataLook up a doctor →

Ahad Sadiq, MD

Hematology & Oncology · Fort Wayne, INNPI 1861525560

Payments from drug & device makers

$3,959,623in general payments, 2019–2025

Across 736 payments — averaging $5379.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.3M
  • E.r. Squibb & Sons, L.L.C.$681K
  • AstraZeneca$539K
  • Biontech SE$431K
  • Genentech, Inc.$217K
  • Daiichi Sankyo Inc.$142K
  • plus $618K from 47 others
$4,778in research payments, 2019–2025

Across 2 payments — averaging $2389.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$4K
  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck74$1,332,623
E.r. Squibb & Sons, L.L.C.201$681,198
AstraZeneca(2 entities)35$538,772
Biontech SE100$431,011
Genentech, Inc.43$216,649
Daiichi Sankyo Inc.28$141,654
F. Hoffmann-la Roche AG28$139,610
Astrazeneca UK Limited2$120,830
Janssen Research & Development, LLC7$84,361
GSK20$55,977
Eli Lilly5$52,720
Mirati Therapeutics, Inc.14$36,342
Amgen17$29,373
Takeda Pharmaceuticals U.S.A., Inc.17$24,584
AbbVie5$22,646
Bristol Myers Squibb5$18,042
Boehringer Ingelheim16$15,244
Roche Products Limited2$7,974
Beigene USA, Inc.2$1,895
Pfizer9$1,675
Gilead(2 entities)5$1,542
Novartis27$1,388
Merck Kgaa1$690
Merck Healthcare Kgaa1$373
Pharmacyclics LLC, An Abbvie Company13$288
Genentech USA, Inc.8$264
Johnson & Johnson7$264
Verastem, Inc.2$242
Organon1$238
Sanofi4$167
Pharmacosmos Therapeutics Inc.1$122
AVEO Pharmaceuticals, Inc.2$120
ADC Therapeutics America, Inc.1$110
Foundation Medicine, Inc.1$98
Deciphera Pharmaceuticals Inc.3$66
Incyte Corporation4$62
Jazz Pharmaceuticals Inc.3$58
Myovant Sciences Inc.2$35
Exelixis Inc.2$31
Seagen Inc.2$29
Dova Pharmaceuticals2$28
EMD Serono, Inc.2$26
Rigel Pharmaceuticals, Inc.2$25
Bayer1$25
Servier Pharmaceuticals LLC1$22
Progenics Pharmaceuticals, Inc.1$20
Sobi, Inc1$20
Acrotech Biopharma Inc.1$19
Karyopharm Therapeutics Inc.1$19
Clovis Oncology, Inc.1$15
Regeneron Healthcare Solutions, Inc.1$14
Lilly USA, LLC1$13
AMAG Pharmaceuticals, Inc.1$11

How this compares

$3,959,623 in reported general payments places this provider in the 95th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana →

Medicare billing

Part B allowed, 2024
$2,815,675
Medicare patients
569
Services billed
139,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fort Wayne

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →